The secondary endpoints are all about marketing and market share for sure. Showing superiority does that.
The primary endpoint is all about getting to market in the first place. Approval is still the name of the game. The business decision (whether guided by the FDA or not) to do it as non-inferiority may have been (and I suspect is) the safest path to approval.
Market Data 
Markets 
AI
